1. Home
  2. CRGX vs THFF Comparison

CRGX vs THFF Comparison

Compare CRGX & THFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • THFF
  • Stock Information
  • Founded
  • CRGX 2021
  • THFF 1984
  • Country
  • CRGX United States
  • THFF United States
  • Employees
  • CRGX N/A
  • THFF N/A
  • Industry
  • CRGX
  • THFF Major Banks
  • Sector
  • CRGX
  • THFF Finance
  • Exchange
  • CRGX Nasdaq
  • THFF Nasdaq
  • Market Cap
  • CRGX 190.0M
  • THFF 625.8M
  • IPO Year
  • CRGX 2023
  • THFF N/A
  • Fundamental
  • Price
  • CRGX $4.16
  • THFF $54.19
  • Analyst Decision
  • CRGX Hold
  • THFF Buy
  • Analyst Count
  • CRGX 7
  • THFF 2
  • Target Price
  • CRGX $4.67
  • THFF $56.50
  • AVG Volume (30 Days)
  • CRGX 586.4K
  • THFF 54.1K
  • Earning Date
  • CRGX 08-11-2025
  • THFF 07-22-2025
  • Dividend Yield
  • CRGX N/A
  • THFF 3.75%
  • EPS Growth
  • CRGX N/A
  • THFF N/A
  • EPS
  • CRGX N/A
  • THFF 4.63
  • Revenue
  • CRGX N/A
  • THFF $215,577,000.00
  • Revenue This Year
  • CRGX $57.81
  • THFF $29.97
  • Revenue Next Year
  • CRGX N/A
  • THFF $2.84
  • P/E Ratio
  • CRGX N/A
  • THFF $11.75
  • Revenue Growth
  • CRGX N/A
  • THFF 9.26
  • 52 Week Low
  • CRGX $3.00
  • THFF $35.62
  • 52 Week High
  • CRGX $25.45
  • THFF $54.63
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 45.07
  • THFF 64.58
  • Support Level
  • CRGX $4.33
  • THFF $51.91
  • Resistance Level
  • CRGX $4.36
  • THFF $54.63
  • Average True Range (ATR)
  • CRGX 0.19
  • THFF 1.18
  • MACD
  • CRGX -0.04
  • THFF 0.23
  • Stochastic Oscillator
  • CRGX 21.76
  • THFF 91.04

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About THFF First Financial Corporation Indiana

First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.

Share on Social Networks: